Skip to main content

EL PAPEL DE LA NEDILACION EN LA ESTEATOHEPATITIS NO ALCOHOLICA Y SU PROGRESION A CIRROSIS Y CANCER HEPATICO

SAF2017-87301-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publication Artículo científico (JournalArticle)

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

  • Fernández Tussy, Pablo
  • Rodríguez Agudo, Rubén
  • Fernández Ramos, David
  • Barbier Torres, Lucía
  • Zubiete Franco, Imanol
  • Davalillo, Sergio López de
  • Herráez, Elisa
  • Goikoetxea Usandizaga, Naroa
  • Lachiondo Ortega, Sofía
  • Simón, Jorge
  • Lopitz Otsoa, Fernando
  • Gutiérrez de Juan, Virginia
  • McCain, Misti V.
  • Perugorría, María J.
  • Mabe, Jon
  • Navasa Mayo, Nicolás
  • Rodrigues, Cecilia M. P.
  • Fabregat, Isabel
  • Boix, Loreto
  • Sapena, Víctor
  • Anguita, Juan
  • Lu, Shelly C.
  • Mato, José M.
  • Banales, Jesus M.
  • Villa, Erica
  • Reeves, Helen L.
  • Bruix, Jordi
  • Reig, María
  • Marín, José J. G.
  • Delgado, Teresa C.
  • Martínez Chantar, María L.
[EN]Dysregulation of miRNAs is a hallmark of cancer, modulating oncogenes, tumor suppressors, and drug responsiveness. The multi-kinase inhibitor sorafenib is one of the first-line drugs for advanced hepatocellular carcinoma (HCC), although the outcome for treated patients is heterogeneous. The identification of predictive biomarkers and targets of sorafenib efficacy are sorely needed. Thus, selected top upregulated miRNAs from the C19MC cluster were analyzed in different hepatoma cell lines compared to immortalized liver human cells, THLE-2 as control. MiR-518d-5p showed the most consistent upregulation among them. Thus, miR-518d-5p was measured in liver tumor/non-tumor samples of two distinct cohorts of HCC patients (n = 16 and n = 20, respectively). Circulating miR-518d-5p was measured in an independent cohort of HCC patients receiving sorafenib treatment (n = 100), where miR-518d-5p was analyzed in relation to treatment duration and patient’s overall survival. In vitro and in vivo studies were performed in human hepatoma BCLC3 and Huh7 cells to analyze the effect of miR-518d-5p inhibition/overexpression during the response to sorafenib. Compared with healthy individuals, miR-518d-5p levels were higher in hepatic and serum samples from HCC patients (n = 16) and in an additional cohort of tumor/non-tumor paired samples (n = 20). MiR-518d-5p, through the inhibition of c-Jun and its mitochondrial target PUMA, desensitized human hepatoma cells and mouse xenograft to sorafenib-induced apoptosis. Finally, serum miR-518d-5p was assessed in 100 patients with HCC of different etiologies and BCLC-stage treated with sorafenib. In BCLC-C patients, higher serum miR-518d-5p at diagnosis was associated with shorter sorafenib treatment duration and survival. Hence, hepatic miR-518d-5p modulates sorafenib resistance in HCC through inhibition of c-Jun/PUMA-induced apoptosis. Circulating miR-518d-5p emerges as a potential lack of response biomarker to sorafenib in BCLC-C HCC patients., SI, This work was supported by grants from NIH (US Department of Health and Human services) R01CA172086 (to S.C.L., J.M.M. and M.L.M.-C.) and P01CA233452 (to S.C.L.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C), MINECO: SAF2017-87301-R, SAF2014-52097-R, RTI2018-096759-A-100, SAF2016-75197-R and SAF2015-64149-R, integrated in the Plan Estatal de Investigación Cientifica y Técnica e Innovación 2017-2020 cofounded by FEDER funds/Development Fund—a way to build Europe (to M.L.M.-C., J.M.M., T.C.D., J.J.G.M., and I.F., respectively), Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain: PI16/00598 and PI19/00819 (to J.J.G.M.), PI15/01132 and PI18/01075 (to J.M.B.), PI14/00399 and PI17/00022 (to M.J.P.), PI18/0358 (to M.R.), BIOEF (Basque Foundation for Innovation and Health Research): EITB Maratoia BIO15/CA/014 and BIO15/CA/016/BD (to M.L.M.-C and J.M.B., respectively); Mitotherapeutix (to M.L.M.-C), Consejería de Educación, Junta de Castilla y León: SA063P17 (J.J.G.M.), Asociación Española Contra el Cáncer (T.C. D, P.F.-T., and M.L.M-C), Basque Government Postdoctoral Program (P.F.-T.), Daniel Alagille award from EASL (to T.C.D.), Asociación Española contra el Cáncer, Canceres raros (M.L.M.-C., J.M.B., and J.J.G.M.), La Caixa Foundation (to M.L.M.-C. and J.M.B.), Ayudas Fundación BBVA a equipos de Investigación Científica 2018 (to M.L.M.-C.), Fondo Europeo de Desarrollo Regional’ (FEDER) (to J.M.B.); CIBERehd, Spain (to J.M.B.); IKERBASQUE, Basque foundation for Science, Spain (to J.M.B.), Department of Health of the Basque Country (2017111010) (to J.M.B.), Euskadi RIS3 (2019222054, 2020333010) (to J.M.B.); Department of Industry of the Basque Country (J.M.B.: Elkartek: KK-2020/00008) (to J.M.B.), Ayudas para apoyar grupos de investigación del sistema Universitario Vasco IT971, Instituto de Salud Carlos III PI18/00768 (J.B.), AECC PI044031 (J.B.), Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement 2014 SGR 605 (J.B.), WCR (AICR) 16-0026 (J.B.), Programma di ricerca Regione-Università 2007–2009 and 2011–2012, Regione Emilia- Romagna (E.V.).
BULERIA. Repositorio Institucional de la Universidad de León
Publication Artículo científico (JournalArticle)

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

  • Fernández Ramos, David
  • Fernández Tussy, Pablo
  • Lopitz Otsoa, Fernando
  • Gutiérrez de Juan, Virginia
  • Navasa Mayo, Nicolás
  • Barbier Torres, Lucía
  • Zubiete Franco, Imanol
  • Simón, Jorge
  • Fernández, Agustín F.
  • Arbelaiz, Ander
  • Aransay, Ana M.
  • Lavín, José Luis
  • Beraza, Naiara
  • Perugorria, Maria J.
  • Banales, Jesus M.
  • Villa, Erica
  • Fraga, Mario F.
  • Anguita, Juan
  • Ávila, Matías A.
  • Berasain, Carmen
  • Iruzibieta, Paula
  • Crespo, Javier
  • Lu, Shelly C.
  • Varela Rey, Marta
  • Mato, José M.
  • Delgado, Teresa C.
  • Martínez Chantar, María L.
[EN]Glycine N-methyltransferase (GNMT) is the most abundant methyltransferase in the liver and a master regulator of the transmethylation flux. GNMT downregulation leads to loss of liver function progressing to fibrosis, cirrhosis, and hepatocellular carcinoma. Moreover, GNMT deficiency aggravates cholestasis-induced fibrogenesis. To date, little is known about the mechanisms underlying downregulation of GNMT levels in hepatic fibrosis and cirrhosis. On this basis, microRNAs are epigenetic regulatory elements that play important roles in liver pathology. In this work, we aim to study the regulation of GNMT by microRNAs during liver fibrosis and cirrhosis. Luciferase assay on the 3ʹUTR-Gnmt was used to confirm in silico analysis showing that GNMT is potentially targeted by the microRNA miR-873-5p. Correlation between GNMT and miR-873-5p in human cholestasis and cirrhosis together with miR-873-5p inhibition in vivo in different mouse models of liver cholestasis and fibrosis [bile duct ligation and Mdr2 (Abcb4)-/- mouse] were then assessed. The analysis of liver tissue from cirrhotic and cholestatic patients, as well as from the animal models, showed that miR-873-5p inversely correlated with the expression of GNMT. Importantly, high circulating miR-873-5p was also detected in cholestastic and cirrhotic patients. Preclinical studies with anti-miR-873-5p treatment in bile duct ligation and Mdr2-/- mice recovered GNMT levels in association with ameliorated inflammation and fibrosis mainly by counteracting hepatocyte apoptosis and cholangiocyte proliferation. In conclusion, miR-873-5p emerges as a novel marker for liver fibrosis, cholestasis, and cirrhosis and therapeutic approaches based on anti-miR-873-5p may be effective treatments for liver fibrosis and cholestatic liver disease., SI, This work was supported by grants from NIH (US Department of Health and Human services)- R01AT001576 (S.C.L., J.M.M., and M.L.M.-C.), Ministerio de Economía, Industria y Competitividad: SAF2017-87301-R (M.L.M.-C.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD (M.L.M.-C.), ELKARTEK 2016, Departamento de Industria del Gobierno Vasco (to M.L.M.-C.), Asociación Española contra el Cáncer (to T.C.D, P.F.-T. and M.L.M.-C.), Mitotherapeutix (to M.L.M.-C.), Daniel Alagille award from EASL (to T.C.D), Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M, J.M.B., and M.A), La Caixa Foundation Program (to M.L.M, J.M.B.), FIS: PI15/00892 (to M.F.F), FIS: PI15/01132 and FIS PI18/01075 (to J.M.B.), (to J.M.B.), FIS: PI14/00399 and PI17/00022 (to M.J.P.), Miguel Servet Program (CON14/00129 to J.M.B.), Ramon y Cajal Program (RYC-2015-17755 to M.J.P.), GRUPIN14-052 (to M.F.), PI14/00962 Instituto Carlos III (to J.B.), AECC Scientific Foundation (to J.B.), World Wide Cancer Research (to J.B.), Programma di Ricerca Regione-Università 2007-2009 and 2011-2012, Regione Emilia-Romagna (to E.V.), “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004 to J.M.B.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M.B.), Department of Health of the Basque Country (2013111173 to J.M.B.; 2015111100 to M.J.P.). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. “Hepacare Project” from Fundación La Caixa, Spain (to M.A.A and C.B.), BiO-Eusko Fundazioa project BIO15/CA/011 (to M.A.A and C.B.). We thank this work produced with the support of a 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (to M.V.R.). We thank MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644).
Docta Complutense
Publication Artículo científico (JournalArticle)

Borrelia burgdorferi infection induces long-term memory-like responses in macrophages with tissue-wide consequences in the heart

  • Barriales, Diego
  • Martín-Ruiz, Itziar
  • Carreras-González, Ana
  • Montesinos-Robledo, Marta
  • Azkargorta, Mikel
  • Iloro, Ibon
  • Escobés, Iraide
  • Martín-Mateos, Teresa
  • Atondo, Estibaliz
  • Palacios, Ainhoa
  • Gonzalez-Lopez, Monika
  • Bárcena, Laura
  • Cortázar, Ana R.
  • Cabrera, Diana
  • Peña-Cearra, Ainize
  • van Liempd, Sebastiaan M.
  • Falcón-Pérez, Juan M.
  • Pascual-Itoiz, Miguel A.
  • Flores Landeira, Juana María
  • Abecia, Leticia
  • Pellon, Aize
  • Martínez-Chantar, Maria Luz
  • Aransay, Ana M.
  • Pascual, Alberto
  • Elortza, Felix
  • Berra, Edurne
  • Lavín, José Luis
  • Rodríguez, Héctor
  • Anguita, Juan
Lyme carditis is an extracutaneous manifestation of Lyme disease characterized by episodes of atrioventricular block of varying degrees and additional, less reported cardiomyopathies. The molecular changes associated with the response to Borrelia burgdorferi over the course of infection are poorly understood. Here, we identify broad transcriptomic and proteomic changes in the heart during infection that reveal a profound down-regulation of mitochondrial components. We also describe the long-term functional modulation of macrophages exposed to live bacteria, characterized by an augmented glycolytic output, increased spirochetal binding and internalization, and reduced inflammatory responses. In vitro, glycolysis inhibition reduces the production of tumor necrosis factor (TNF) by memory macrophages, whereas in vivo, it produces the reversion of the memory phenotype, the recovery of tissue mitochondrial components, and decreased inflammation and spirochetal burdens. These results show that B. burgdorferi induces long-term, memory-like responses in macrophages with tissue-wide consequences that are amenable to be manipulated in vivo
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

  • Fernández Fondevila, Marcos
  • Fernández, Uxía
  • Heras Domínguez, Violeta
  • Parracho Martínez, Tamara
  • González Rellán, María Jesús
  • Novoa Deaño, Eva María
  • Porteiro Couto, Begoña
  • Alonso, Cristina
  • Mayo, Rebeca
  • Silva Lima, Natália da
  • Iglesias García, Cristina
  • Filliol, Aveline
  • Senra Viñas, Ana
  • Delgado, Teresa
  • Woodhoo, Ashwin
  • Herrero, Laura
  • Serra, Dolors
  • Prevot, Vincent
  • Schwaninger, Markus
  • López Pérez, Miguel A.
  • Diéguez González, Carlos
  • Millet, Óscar
  • Mato de la Paz, José María
  • Cubero Palero, Francisco Javier
  • Varela Rey, Marta María
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martínez Chantar, María Luz
  • Schwabe, Robert F.
  • Nogueiras Pozo, Rubén
One of the most common types of fibrotic liver occurs in patients with non-alcoholic fatty liver disease (NAFLD), which may develop into non-alcoholic steatohepatitis (NASH). Hepatic stellate cells (HSCs) are the primary fibrogenic cell type activated following liver injury, moving from a quiescent phenotype rich in vitamin A into activated myofibroblast-like cells with proliferative and migratory properties.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

O-GlcNAcylated p53 in the liver modulates hepatic glucose production

  • González Rellán, María Jesús
  • Fernández Fondevila, Marcos
  • Fernández Paz, Uxía
  • Rodríguez Murueta-Goyena, Amaia
  • Varela Rey, Marta María
  • Veyrat-Durebex, Christelle
  • Seoane Ruzo, Samuel
  • Bernardo, Ganeko
  • Lopitz-Otsoa, Fernando
  • Fernández Ramos, David
  • Bilbao, Jon
  • Iglesias López, Cristina
  • Novoa Deaño, Eva María
  • Ameneiro Quiñoy, Cristina
  • Senra, Ana
  • Beiroa, Daniel
  • Cuñarro, Juan
  • Chantada Vázquez, María del Pilar
  • García Vence, María
  • Bravo López, Susana Belén
  • Silva Lima, Natalia Da
  • Porteiro Couto, Begoña
  • Carneiro Freire, Carmen
  • Vidal Figueroa, Anxo
  • Tovar Carro, Sulay A.
  • Müller, Timo D.
  • Ferno, Johan
  • Guallar Artal, Diana
  • Fidalgo Pérez, Miguel Ángel
  • Sabio, Guadalupe
  • Herzig, Stephan
  • Yang, Won Ho
  • Cho, Jin Won
  • Martínez Chantar, María Luz
  • Pérez Fernández, Román
  • López Pérez, Miguel A.
  • Diéguez González, Carlos
  • Mato, José M.
  • Millet, Óscar
  • Coppari, Roberto
  • Woodhoo, Ashwin
  • Fruhbeck, Gema
  • Nogueiras Pozo, Rubén
p53 regulates several signaling pathways to maintain the metabolic homeostasis of cells and modulates the cellular response to stress. Deficiency or excess of nutrients causes cellular metabolic stress, and we hypothesized that p53 could be linked to glucose maintenance. We show here that upon starvation hepatic p53 is stabilized by O-GlcNAcylation and plays an essential role in the physiological regulation of glucose homeostasis. More specifically, p53 binds to PCK1 promoter and regulates its transcriptional activation, thereby controlling hepatic glucose production. Mice lacking p53 in the liver show a reduced gluconeogenic response during calorie restriction. Glucagon, adrenaline and glucocorticoids augment protein levels of p53, and administration of these hormones to p53 deficient human hepatocytes and to liver-specific p53 deficient mice fails to increase glucose levels. Moreover, insulin decreases p53 levels, and over-expression of p53 impairs insulin sensitivity. Finally, protein levels of p53, as well as genes responsible of O-GlcNAcylation are elevated in the liver of type 2 diabetic patients and positively correlate with glucose and HOMA-IR. Overall these results indicate that the O-GlcNAcylation of p53 plays an unsuspected key role regulating in vivo glucose homeostasis
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Nátalia da Silva
  • Fernández Fondevila, Marcos
  • Novoa Deaño, Eva María
  • Buqué, Xabier
  • Mercado Gómez, María
  • Gallet, Sarah
  • González Rellán, María Jesús
  • Fernández Paz, Uxía
  • Loyens, Anne
  • García Vence, María
  • Chantada Vázquez, María del Pilar
  • Bravo López, Susana Belén
  • Marañón Barnusell, Patricia
  • Senra Viñas, Ana
  • Escudero Pérez, Adriana
  • Leiva Arjona, Magdalena
  • Guallar Artal, Diana
  • Fidalgo Pérez, Miguel Ángel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio Buzo, Guadalupe
  • Varela Rey, Marta María
  • Cardoso Delgado, Teresa
  • Montero Vallejo, Rocío
  • Ampuero, Javier
  • López Pérez, Miguel A.
  • Diéguez González, Carlos
  • Herrero, Laura
  • Serra Cucurull, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo García, Javier
  • Martínez Chantar, María Luz
  • García Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras Pozo, Rubén
Non-alcoholic fatty liver disease (NAFLD) is a major health threat in both developed and developing countries and is a precursor of the more advanced liver diseases, including non-alcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Currently, understanding the multiple and complex molecular pathways implicated in NAFLD onset and progression is a major priority. The transcription factor p63, which belongs to a family comprising p53, p63, and p73,1 is one of many factors that contributes to the development of liver steatosis. The role of p63 as a tumor suppressor and in cell maintenance and renewal is well studied, but we have recently reported that it is also relevant in the control of lipid metabolism.2 p63 encodes multiple isoforms that can be grouped into 2 categories; isoforms with an acidic transactivation domain (TA) and those without this domain (domain negative). The TAp63α isoform is elevated in the liver of animal models of NAFLD as well as in liver biopsies from obese patients with NAFLD. Furthermore, downregulation of p63α in the liver attenuates liver steatosis in diet-induced obese (DIO) mice, while the activation of TAp63α increases hepatic fat content, mediated by the activation of IKKβ and endoplasmic reticulum stress.2 A specialized form of autophagy that degrades lipid droplets, termed “lipophagy”, is a major pathway of lipid mobilization in hepatocytes. Lipophagy is elevated in hepatoma cells upon exposure to free fatty acids,3 and reduces the fatty acid load in mouse hepatocytes.4 Its impairment has been associated with the development of fatty liver and insulin resistance3,5; in contrast, the autophagic flux is increased during the activation of hepatic stellate cells.6 In the present study, we used an unbiased proteomics approach to gain insight into novel proteins modulating lipid metabolism in the liver of mice with genetic knockdown or overexpression of TAp63α. We found that autophagy-related gene 3 (ATG3) was upregulated by TAp63α activation and downregulated after p63α inhibition. ATG3 is elevated in several animal models of NAFLD and in the liver of patients with NAFLD. Genetic overexpression of ATG3 increased the lipid load in hepatocytes, while its repression alleviated TAp63α- and diet-induced steatosis. ATG3 exerted its role in lipid metabolism by regulating SIRT1 and mitochondrial function. Collectively, these findings identify ATG3 as a novel factor implicated in the development of steatosis
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

  • Serrano Maciá, Marina
  • Simón, Jorge
  • González Rellán, María Jesús
  • Azkargorta, Mikel
  • Goikoetxea-Usandizaga, Naroa
  • Lopitz Otsoa, Fernando
  • Sáenz de Urturi, Diego
  • Rodríguez Agudo, Rubén
  • Lachiondo-Ortega, Sofia
  • Mercado Gómez, María
  • Gutiérrez de Juan, Virginia
  • Bizkarguenaga-Uribiarte, Maider
  • Fernández-Ramos, David
  • Buqué, Xabier
  • Baselli, Guido Alessandro
  • Valenti, Luca
  • Iruzubieta, Paula
  • Crespo, Javier
  • Villa, Erica
  • Banales, Jesus
  • Avila, Matias A.
  • Marin, Jose
  • Aspichueta, Patricia
  • Sutherland, James D.
  • Barrio, Rosa
  • Mayor, Ugo
  • Elortza, Felix
  • Xirodimas, Dimitris
  • Nogueiras Pozo, Rubén
  • Delgado, Teresa
  • Martínez Chantar, María Luz
Objective: Neddylation is a druggable and reversible ubiquitin-like post-translational modification upregulated in many diseases, including liver fibrosis, hepatocellular carcinoma, and more recently, non-alcoholic fatty liver disease (NAFLD). Herein, we propose to address the effects of neddylation inhibition and the underlying mechanisms in pre-clinical models of NAFLD. Methods: Hepatic neddylation measured by immunohistochemical analysis and NEDD8 serum levels measured by ELISA assay were evaluated in NAFLD clinical and pre-clinical samples. The effects of neddylation inhibition by using a pharmacological small inhibitor, MLN4924, or molecular approaches were assessed in isolated mouse hepatocytes and pre-clinical mouse models of diet-induced NAFLD, male adult C57BL/6 mice, and the AlfpCre transgenic mice infected with AAV-DIO-shNedd8. Results: Neddylation inhibition reduced lipid accumulation in oleic acid-stimulated mouse primary hepatocytes and ameliorated liver steatosis, preventing lipid peroxidation and inflammation in the mouse models of diet-induced NAFLD. Under these conditions, increased Deptor levels and the concomitant repression of mTOR signaling were associated with augmented fatty acid oxidation and reduced lipid content. Moreover, Deptor silencing in isolated mouse hepatocytes abolished the anti-steatotic effects mediated by neddylation inhibition. Finally, serum NEDD8 levels correlated with hepatic neddylation during the disease progression in the clinical and pre-clinical models. Conclusions: Overall, the upregulation of Deptor, driven by neddylation inhibition, is proposed as a novel effective target and therapeutic approach to tackle NAFLD
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans

  • Cruces-Sande, Marta
  • Vila-Bedmar, Rocío
  • Arcones, Alba C.
  • González-Rodríguez, Águeda
  • Rada, Patricia
  • Gutiérrez-de-Juan, Virginia
  • Vargas-Castrillón, Javier
  • Iruzubieta, Paula
  • Sánchez-González, Cristina
  • Formentini, Laura
  • Crespo, Javier
  • García-Monzón, Carmelo
  • Martínez-Chantar, María Luz
  • Valverde, Ángela M.
  • Mayor Jr., Federico
  • Murga, Cristina
Insulin resistance (IR) and obesity are important risk factors for non-alcoholic fatty liver disease (NAFLD). G protein-coupled receptor kinase 2 (GRK2) is involved in the development of IR and obesity in vivo. However, its possible contribution to NAFLD and/or non-alcoholic steatohepatitis (NASH) independently of its role on IR or fat mass accretion has not been explored. Here, we used wild-type (WT) or GRK2 hemizygous (GRK2±) mice fed a high-fat diet (HFD) or a methionine and choline-deficient diet (MCD) as a model of NASH independent of adiposity and IR. GRK2± mice were protected from HFD-induced NAFLD. Moreover, MCD feeding caused an increased in triglyceride content and liver-to-body weight ratio in WT mice, features that were attenuated in GRK2± mice. According to their NAFLD activity score, MCD-fed GRK2± mice were diagnosed with simple steatosis and not overt NASH. They also showed reduced expression of lipogenic and lipid-uptake markers and less signs of inflammation in the liver. GRK2± mice preserved hepatic protective mechanisms as enhanced autophagy and mitochondrial fusion and biogenesis, together with reduced endoplasmic reticulum stress. GRK2 protein was increased in MCD-fed WT but not in GRK2± mice, and enhanced GRK2 expression potentiated palmitic acid-triggered lipid accumulation in human hepatocytes directly relating GRK2 levels to steatosis. GRK2 protein and mRNA levels were increased in human liver biopsies from simple steatosis or NASH patients in two different human cohorts. Our results describe a functional relationship between GRK2 levels and hepatic lipid accumulation and implicate GRK2 in the establishment and/or development of NASH., Ministerio de Economia y Competitividad (MINECO/FEDER), Spain (grants SAF2014-55511-R and SAF2017-84125-R to F.M and C. M., grant SAF2015-65267-R to A.M.V., grant SAF2016-76028R to L.F. and SAF2017-87301-R to M.L.M.-C); Comunidad de Madrid-B2017/BMD-3671-INFLAMUNE to F.M.; Gobierno Vasco-Departamento de Salud 2013111114 and EITB Maratoia BIO15/CA/014 (to M.L.M.C); European Foundation for the Study of Diabetes (EFSD) Novo Nordisk Partnership for Diabetes Research in Europe Grant (to F.M.); Asociacion Espanola contra el Cancer (M.L.M-C) and Fundacion Ramon Areces (to C.M.). Instituto de Salud Carlos III (with European FEDER contribution) funds CIBERCV (grant CB16/11/00278 to F.M), CIBERDEM and CIBERehd, Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

GRK2-Dependent HuR Phosphorylation Regulates HIF1α Activation under Hypoxia or Adrenergic Stress

  • Reglero, Clara
  • Lafarga, Vanesa
  • Rivas, Verónica
  • Albitre, Ángela
  • Ramos Parrón, Paula
  • Berciano, Susana R.
  • Tapia, Olga
  • Martínez-Chantar, María Luz
  • Mayor Menéndez, Federico
  • Penela, Petronila
© 2020 by the authors., Adaptation to hypoxia is a common feature in solid tumors orchestrated by oxygen-dependent and independent upregulation of the hypoxia-inducible factor-1α (HIF-1α). We unveiled that G protein-coupled receptor kinase (GRK2), known to be overexpressed in certain tumors, fosters this hypoxic pathway via phosphorylation of the mRNA-binding protein HuR, a central HIF-1α modulator. GRK2-mediated HuR phosphorylation increases the total levels and cytoplasmic shuttling of HuR in response to hypoxia, and GRK2-phosphodefective HuR mutants show defective cytosolic accumulation and lower binding to HIF-1α mRNA in hypoxic Hela cells. Interestingly, enhanced GRK2 and HuR expression correlate in luminal breast cancer patients. GRK2 also promotes the HuR/HIF-1α axis and VEGF-C accumulation in normoxic MCF7 breast luminal cancer cells and is required for the induction of HuR/HIF1-α in response to adrenergic stress. Our results point to a relevant role of the GRK2/HuR/HIF-1α module in the adaptation of malignant cells to tumor microenvironment-related stresses., This research was funded by the Instituto de Salud Carlos III: PI17-00576; Ministerio de Economía, Industria y Competitividad, Gobierno de España: SAF2017-84125-R; Ministerio de Economía, Industria y Competitividad, Gobierno de España: SAF2017-87301-R; Instituto de Salud Carlos III: CIBERCV CB16/11/00278; Instituto de Salud Carlos III: PI14-00435; Fundación Ramón Areces and the Comunidad de Madrid: B2017/BMD-3671-INFLAMUNE., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: a machine-learning approach

  • Urman, Jesús M.
  • Herranz, José M.
  • Uriarte, Iker
  • Rullán, María
  • Oyón, Daniel
  • González, Belén
  • Fernandez-Urién, Ignacio
  • Carrascosa, Juan
  • Bolado, Federico
  • Zabalza, Lucía
  • Arechederra, María
  • Alvarez-Sola, Gloria
  • Colyn, Leticia
  • Latasa, Maria U.
  • Puchades-Carrasco, Leonor
  • Pineda-Lucena, Antonio
  • Iraburu, María J.
  • Iruarrizaga-Lejarreta, Marta
  • Alonso, Cristina
  • Sangro, Bruno
  • Purroy, Ana
  • Gil, Isabel
  • Carmona, Lorena
  • Cubero, Francisco Javier
  • Martínez-Chantar, María Luz
  • Banales, Jesús M.
  • Romero, Marta R.
  • Macías, Rocío I. R.
  • Monte, Maria J.
  • Marín, José J. G.
  • Vila, Juan J.
  • Corrales, Fernando J.
  • Berasain, Carmen
  • Fernández-Barrena, Maite G.
  • Ávila, Matías A.
Cholangiocarcinoma (CCA) and pancreatic adenocarcinoma (PDAC) may lead to the development of extrahepatic obstructive cholestasis. However, biliary stenoses can also be caused by benign conditions, and the identification of their etiology still remains a clinical challenge. We performed metabolomic and proteomic analyses of bile from patients with benign (n = 36) and malignant conditions, CCA (n = 36) or PDAC (n = 57), undergoing endoscopic retrograde cholangiopancreatography with the aim of characterizing bile composition in biliopancreatic disease and identifying biomarkers for the differential diagnosis of biliary strictures. Comprehensive analyses of lipids, bile acids and small molecules were carried out using mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (1H-NMR) in all patients. MS analysis of bile proteome was performed in five patients per group. We implemented artificial intelligence tools for the selection of biomarkers and algorithms with predictive capacity. Our machine-learning pipeline included the generation of synthetic data with properties of real data, the selection of potential biomarkers (metabolites or proteins) and their analysis with neural networks (NN). Selected biomarkers were then validated with real data. We identified panels of lipids (n = 10) and proteins (n = 5) that when analyzed with NN algorithms discriminated between patients with and without cancer with an unprecedented accuracy., This research was funded by: Instituto de Salud Carlos III (ISCIII) co-financed by Fondo Europeo de Desarrollo Regional (FEDER) Una manera de hacer Europa, grant numbers: PI16/01126 (M.A.A.), PI19/00819 (M.J.M. and J.J.G.M.), PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129 (J.M.B.); Fundación Científica de la Asociación Española Contra el Cáncer (AECC Scientific Foundation), grant name: Rare Cancers 2017 (J.M.U., M.L.M., J.M.B., M.J.M., R.I.R.M., M.G.F.-B., C.B., M.A.A.); Gobierno de Navarra Salud, grant number 58/17 (J.M.U., M.A.A.); La Caixa Foundation, grant name: HEPACARE (C.B., M.A.A.); AMMF The Cholangiocarcinoma Charity, UK, grant number: 2018/117 (F.J.C. and M.A.A.); PSC Partners US, PSC Supports UK, grant number 06119JB (J.M.B.); Horizon 2020 (H2020) ESCALON project, grant number H2020-SC1-BHC-2018–2020 (J.M.B.); BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia, grant numbers BIO15/CA/016/BD (J.M.B.) and BIO15/CA/011 (M.A.A.). Department of Health of the Basque Country, grant number 2017111010 (J.M.B.). La Caixa Foundation, grant number: LCF/PR/HP17/52190004 (M.L.M.), Mineco-Feder, grant number SAF2017-87301-R (M.L.M.), Fundación BBVA grant name: Ayudas a Equipos de Investigación Científica Umbrella 2018 (M.L.M.). MCIU, grant number: Severo Ochoa Excellence Accreditation SEV-2016-0644 (M.L.M.). Part of the equipment used in this work was co-funded by the Generalitat Valenciana and European Regional Development Fund (FEDER) funds (PO FEDER of Comunitat Valenciana 2014–2020). Gobierno de Navarra fellowship to L.C. (Leticia Colyn); AECC post-doctoral fellowship to M.A.; Ramón y Cajal Program contracts RYC-2014-15242 and RYC2018-024475-1 to F.J.C. and M.G.F.-B., respectively. The generous support from: Fundación Eugenio Rodríguez Pascual, Fundación Echébano, Fundación Mario Losantos, Fundación M Torres and Mr. Eduardo Avila are acknowledged. The CNB-CSIC Proteomics Unit belongs to ProteoRed, PRB3-ISCIII, supported by grant PT17/0019/0001 (F.J.C.). Comunidad de Madrid Grant B2017/BMD-3817 (F.J.C.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Borrelia burgdorferi infection induces long-term memory-like responses in macrophages with tissue-wide consequences in the heart

  • Barriales, Diego
  • Martín-Ruiz, Itziar
  • Carreras-González, Ana
  • Montesinos-Robledo, Marta
  • Azkargorta, Mikel
  • Iloro, Ibon
  • Escobés, Iraide
  • Martín-Mateos, Teresa
  • Atondo, Estíbaliz
  • Palacios, Ainhoa
  • González-López, Mónika
  • Bárcena, Laura
  • Cortázar, Ana R.
  • Cabrera, Diana
  • Peña-Cearra, Ainize
  • van Liempd, Sebastiaan M.
  • Falcón-Pérez, Juan M.
  • Pascual-Itoiz, Miguel Ángel
  • Flores, Juana María
  • Abecia, Leticia
  • Pellón, Aize
  • Martínez-Chantar, María Luz
  • Aransay, Ana M.
  • Pascual Bravo, Alberto
  • Elortza, Felix
  • Berra, Edurne
  • Lavín, José Luis
  • Rodríguez, Héctor
  • Anguita, Juan
Lyme carditis is an extracutaneous manifestation of Lyme disease characterized by episodes of atrioventricular block of varying degrees and additional, less reported cardiomyopathies. The molecular changes associated with the response to Borrelia burgdorferi over the course of infection are poorly understood. Here, we identify broad transcriptomic and proteomic changes in the heart during infection that reveal a profound down-regulation of mitochondrial components. We also describe the long-term functional modulation of macrophages exposed to live bacteria, characterized by an augmented glycolytic output, increased spirochetal binding and internalization, and reduced inflammatory responses. In vitro, glycolysis inhibition reduces the production of tumor necrosis factor (TNF) by memory macrophages, whereas in vivo, it produces the reversion of the memory phenotype, the recovery of tissue mitochondrial components, and decreased inflammation and spirochetal burdens. These results show that B. burgdorferi induces long-term, memory-like responses in macrophages with tissue-wide consequences that are amenable to be manipulated in vivo., Supported by grants from the Spanish Ministry of Science, Innovation and Universities (MCIU) co-financed with FEDER funds (SAF2015-65327-R and RTI2018-096494-B-100 to JA; BFU2016-76872-R to EB, AGL2017-86757-R to LA, SAF2017-87301-R to MLMC, SAF2015-64111-R to AP, SAF2015-73549-JIN to HR), Instituto de Salud Carlos III (PIE13/0004 to AP), the Basque Government Department of Health (2015111117 to LA), the Basque Foundation for Innovation and Health Research (BIOEF), through the EiTB Maratoia grant BIO15/CA/016/BS to MLMC, the regional Government of Andalusia co-funded by CEC and FEDER funds (Proyectos de Excelencia P12-CTS-2232) and Fundación Domingo Martínez (to AP). LA is supported by the Ramon y Cajal program (RYC-2013-13666). DB, MMR and TMM are recipients of MCIU FPI fellowships. ACG and AP are recipients of fellowships form the Basque Government. APC is a recipient of a fellowship from the University of the Basque Country. We thank the MCIU for the Severo Ochoa Excellence accreditation (SEV-2016-0644), the Basque Department of Industry, Tourism and Trade (Etortek and Elkartek programs), the Innovation Technology Department of the Bizkaia Province and the CIBERehd network. DB and JA are supported by a grant from the Jesús de Gangoiti Barrera Foundation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

  • Simón, Jorge
  • Goikoetxea-Usandizaga, Naroa
  • Serrano-Maciá, Marina
  • Fernández-Ramos, David
  • Sáenz de Urturi, Diego
  • Gruskos, Jessica J.
  • Fernández-Tussy, Pablo
  • Lachiondo-Ortega, Sofía
  • González-Recio, Irene
  • Rodríguez-Agudo, Rubén
  • Gutiérrez de Juan, Virginia
  • Rodríguez-Iruretagoyena, Begoña
  • Varela-Rey, Marta
  • Gimenez-Mascarell, Paula
  • Mercado-Gómez, María
  • Gómez-Santos, Beatriz
  • Fernández-Rodríguez, Carmen
  • Lopitz-Otsoa, Fernando
  • Bizkarguenaga, Maider
  • Dames, Sibylle
  • Schaeper, Ute
  • Martín, Franz
  • Sabio, Guadalupe
  • Iruzubieta, Paula
  • Crespo, Javier
  • Aspichueta, Patricia
  • Chu, Kevan H.-Y.
  • Buccella, Daniela
  • Martín, César
  • Cardoso Delgado, Teresa de Jesús
  • Martínez-Cruz, Luis Alfonso
  • Martínez-Chantar, María Luz
Background & Aims: Perturbations of intracellular magnesium (Mg) homeostasis have implications for cell physiology. The cyclin M family, CNNM, perform key functions in the transport of Mg across cell membranes. Herein, we aimed to elucidate the role of CNNM4 in the development of non-alcoholic steatohepatitis (NASH). Methods: Serum Mg levels and hepatic CNNM4 expression were characterised in clinical samples. Primary hepatocytes were cultured under methionine and choline deprivation. A 0.1% methionine and choline-deficient diet, or a choline-deficient high-fat diet were used to induce NASH in our in vivo rodent models. Cnnm4 was silenced using siRNA, in vitro with DharmaFECT and in vivo with Invivofectamine® or conjugated to N-acetylgalactosamine. Results: Patients with NASH showed hepatic CNNM4 overexpression and dysregulated Mg levels in the serum. Cnnm4 silencing ameliorated hepatic lipid accumulation, inflammation and fibrosis in the rodent NASH models. Mechanistically, CNNM4 knockdown in hepatocytes induced cellular Mg accumulation, reduced endoplasmic reticulum stress, and increased microsomal triglyceride transfer activity, which promoted hepatic lipid clearance by increasing the secretion of VLDLs. Conclusions: CNNM4 is overexpressed in patients with NASH and is responsible for dysregulated Mg transport. Hepatic CNNM4 is a promising therapeutic target for the treatment of NASH. Lay summary: Cyclin M4 (CNNM4) is overexpressed in non-alcoholic steatohepatitis (NASH) and promotes the export of magnesium from the liver. The liver-specific silencing of Cnnm4 ameliorates NASH by reducing endoplasmic reticulum stress and promoting the activity of microsomal triglyceride transfer protein., Ministerio de Ciencia e Innovación, Programa Retos-Colaboración RTC2019-007125-1 (for JS and MLM-C); Instituto de Salud Carlos III, Proyectos de Investigación en Salud DTS20/00138 (for JS and MLM-C); Departamento de Industria del Gobierno Vasco (for MLM-C); Ministerio de Ciencia, Innovación y Universidades MICINN: SAF2017-87301-R and RTI2018-096759-A-100 integrado en el Plan Estatal de Investigación Cientifica y Técnica y Innovación, cofinanciado con Fondos FEDER (for MLM-C and TCD, respectively); BIOEF (Basque Foundation for Innovation and Health Research); EITB Maratoia BIO15/CA/014; Asociación Española contra el Cáncer (MLM-C, TCD); Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (for MLM); La Caixa Foundation Program (for MLM); Fundacion BBVA UMBRELLA project (for MLM); BFU2015-70067-REDC, BFU2016-77408-R, and BES-2017- 080435 (MINECO / FEDER, UE) and the FIGHT-CNNM2 project from the EJP RD Joint Transnational Call (JTC2019) (Ref. AC19/ 00073) (for LAM-C); RTI2018-095134-B-100 and Grupos de Investigación del Sistema Universitario Vasco (IT971-16) (for PA); National Institutes of Health under grant CA217817 (for DB); AGL2014-54585-R, AGL-2017-86927-R and EQC2018-004897-P from MINECO; PC0148-2016-0149 and PAI-BIO311 from Junta de Andalucía (for FM). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. We thank Silence Therapeutics plc. for the financial support provided. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV- 2016-0644).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

  • Lima, Natália da Silva
  • Fondevila, Marcos F.
  • Nóvoa, Eva
  • Buqué, Xabier
  • Mercado-Gómez, María
  • Gallet, Sarah
  • González-Rellán, María Jesús
  • Fernández, Uxía
  • Loyens, Anne
  • García-Vence, María
  • Chantada-Vázquez, María del Pilar
  • Bravo, Susana Belén
  • Marañón, Patricia
  • Senra, Ana
  • Escudero, Adriana
  • Leiva, Magdalena
  • Guallar, Diana
  • Fidalgo, Miguel
  • Gomes, Pedro
  • Claret, Marc
  • Sabio, Guadalupe
  • Varela-Rey, Marta
  • Delgado, Teresa C.
  • Montero-Vallejo, Rocío
  • Ampuero, Javier
  • López, Miguel
  • Diéguez, Carlos
  • Herrero, Laura
  • Serra, Dolors
  • Schwaninger, Markus
  • Prevot, Vincent
  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
  • Iruzubieta, Paula
  • Crespo, Javier
  • Martínez-Chantar, María Luz
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Aspichueta, Patricia
  • Nogueiras, Rubén
[Background & Aims] Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation process, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes to non-alcoholic fatty liver disease (NAFLD) remains unknown., [Methods] By performing proteomic analysis on livers from mice with genetic manipulation of hepatic p63, a regulator of fatty acid metabolism, we identified ATG3 as a new target downstream of p63. ATG3 was evaluated in liver samples from patients with NAFLD. Further, genetic manipulation of ATG3 was performed in human hepatocyte cell lines, primary hepatocytes and in the livers of mice., [Results] ATG3 expression is induced in the liver of animal models and patients with NAFLD (both steatosis and non-alcoholic steatohepatitis) compared with those without liver disease. Moreover, genetic knockdown of ATG3 in mice and human hepatocytes ameliorates p63- and diet-induced steatosis, while its overexpression increases the lipid load in hepatocytes. The inhibition of hepatic ATG3 improves fatty acid metabolism by reducing c-Jun N-terminal protein kinase 1 (JNK1), which increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a (CPT1a), and mitochondrial function. Hepatic knockdown of SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial activity. Unexpectedly, these effects are independent of an autophagic action., [Conclusions] Collectively, these findings indicate that ATG3 is a novel protein implicated in the development of steatosis., This work has been supported by grants from FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (PA: RTI2018-095134-B-100; DS and LH: SAF2017-83813-C3-1-R; MLMC: RTC2019-007125-1; CD: BFU2017-87721; ML: RTI2018–101840-B-I00; GS; PID2019-104399RB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; MLMC: SAF2017-87301-R; TCD: RTI2018-096759-A-100), FEDER/Instituto de Salud Carlos III (AGR: PI19/00123), Xunta de Galicia (ML: 2016-PG068; RN: 2015-CP080 and 2016-PG057), Fundación BBVA (RN, GS and MLM), Proyectos Investigación en Salud (MLMC: DTS20/00138), Sistema Universitario Vasco (PA: IT971-16); Fundación Atresmedia (ML and RN), Fundación La Caixa (M.L., R.N. and M.C.), Gilead Sciences International Research Scholars Program in Liver Disease (MVR), Marató TV3 Foundation (DS: 201627), Government of Catalonia (DS: 2017SGR278) and European Foundation for the Study of Diabetes (RN and GS). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to RN, VP and MS). Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn), Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem). CIBERobn, CIBERehd and CIBERdem are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation

  • Fernández-Ramos, David
  • Lopitz-Otsoa, Fernando
  • Delacruz-Villar, Laura
  • Bilbao, Jon
  • Pagano, Martina
  • Mosca, Laura
  • Bizkarguenaga, Maider
  • Serrano-Maciá, Marina
  • Azkargorta, Mikel
  • Iruarrizaga-Lejarreta, Marta
  • Sot, Jesús
  • Tsvirkun, Darya
  • Liempd, Sebastiaan Martijn van
  • Goñi, Félix M.
  • Alonso, Cristina
  • Martínez-Chantar, María Luz
  • Elortza, Félix
  • Hayardeny, Liat
  • Lu, Shelly C.
  • Mato, José M.
[Background] Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis. In a phase IIb clinical trial in patients with nonalcoholic steatohepatitis (NASH), 52 wk of treatment with Aramchol reduced blood levels of glycated hemoglobin A1c, an indicator of glycemic control., [Aim] o assess lipid and glucose metabolism in mouse hepatocytes and in a NASH mouse model [induced with a 0.1% methionine and choline deficient diet (0.1MCD)] after treatment with Aramchol., [Methods] Isolated primary mouse hepatocytes were incubated with 20 μmol/L Aramchol or vehicle for 48 h. Subsequently, analyses were performed including Western blot, proteomics by mass spectrometry, and fluxomic analysis with 13C-uniformly labeled glucose. For the in vivo part of the study, male C57BL/6J mice were randomly fed a control or 0.1MCD for 4 wk and received 1 or 5 mg/kg/d Aramchol or vehicle by intragastric gavage for the last 2 wk. Liver metabolomics were assessed using ultra-high-performance liquid chromatography-time of flight-MS for the determination of glucose metabolism-related metabolites., [Results] Combination of proteomics and Western blot analyses showed increased AMPK activity while the activity of nutrient sensor mTORC1 was decreased by Aramchol in hepatocytes. This translated into changes in the content of their downstream targets including proteins involved in fatty acid (FA) synthesis and oxidation [P-ACCα/β(S79), SCD1, CPT1A/B, HADHA, and HADHB], oxidative phosphorylation (NDUFA9, NDUFB11, NDUFS1, NDUFV1, ETFDH, and UQCRC2), tricarboxylic acid (TCA) cycle (MDH2, SUCLA2, and SUCLG2), and ribosome (P-p70S6K[T389] and P-S6[S235/S236]). Flux experiments with 13C-uniformely labeled glucose showed that TCA cycle cataplerosis was reduced by Aramchol in hepatocytes, as indicated by the increase in the number of rounds that malate remained in the TCA cycle. Finally, liver metabolomic analysis showed that glucose homeostasis was improved by Aramchol in 0.1MCD fed mice in a dose-dependent manner, showing normalization of glucose, G6P, F6P, UDP-glucose, and Rbl5P/Xyl5P., [Conclusion] Aramchol exerts its effect on glucose and lipid metabolism in NASH through activation of AMPK and inhibition of mTORC1, which in turn activate FA β-oxidation and oxidative phosphorylation., Supported by the National Institutes of Health Grant, No. R01CA172086;Plan Nacional of I+D, No. SAF2017-88041-R;Ministerio de Economía y Competitividad de España, No. SAF2017-87301-R;Asociación Española contra el Cáncer, No. AECC17/302;Ayudas Fundación BBVA a equipos de Investigación Científica 2018;Fondo Europeo de Desarrollo Regional, Ministerio de Economia y Competitividad de España, No. PGC2018-099857-B-I00;Basque Government Grants, No. IT1264-19;Ministerio de Economia y Competitividad de España for the Severo Ochoa Excellence Accreditation, No. SEV-2016-0644., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease

  • Gómez-Santos, Beatriz
  • Sáenz de Urturi, Diego
  • Núñez-García, Maitane
  • González-Romero, Francisco
  • Buqué, Xabier
  • Aurrekoetxea, Igor
  • Gutiérrez de Juan, Virginia
  • González-Rellán, María J.
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Mosteiro, Lorena
  • Errazti, Gaizka
  • Mifsut, Patricia
  • Gaztambide, Sonia
  • Castaño, Luis
  • Martín, César
  • Nogueiras, Rubén
  • Martínez-Chantar, María Luz
  • Syn, Wing-Kin
  • Aspichueta, Patricia
Osteopontin (OPN), a senescence-associated secretory phenotype factor, is increased in patients with nonalcoholic fatty liver disease (NAFLD). Cellular senescence has been associated with age-dependent hepatosteatosis. Thus, we investigated the role of OPN in the age-related hepatosteatosis. For this, human serum samples, animal models of aging, and cell lines in which senescence was induced were used. Metabolic fluxes, lipid, and protein concentration were determined. Among individuals with a normal liver, we observed a positive correlation between serum OPN levels and increasing age. This correlation with age, however, was absent in patients with NAFLD. In wild-type (WT) mice, serum and liver OPN were increased at 10 months old (m) along with liver p53 levels and remained elevated at 20m. Markers of liver senescence increased in association with synthesis and concentration of triglycerides (TG) in 10m OPN-deficient (KO) hepatocytes when compared to WT hepatocytes. These changes in senescence and lipid metabolism in 10m OPN-KO mice liver were associated with the decrease of 78 kDa glucose-regulated protein (GRP78), induction of ER stress, and the increase in fatty acid synthase and CD36 levels. OPN deficiency in senescent cells also diminished GRP78, the accumulation of intracellular TG, and the increase in CD36 levels. In 20m mice, OPN loss led to increased liver fibrosis. Finally, we showed that OPN expression in vitro and in vivo was regulated by p53. In conclusion, OPN deficiency leads to earlier cellular senescence, ER stress, and TG accumulation during aging. The p53-OPN axis is required to inhibit the onset of age-related hepatosteatosis., This work was supported by Ayudas para apoyar grupos de investigación del sistema Universitario Vasco (IT971-16 to P.A.), MINECO-FEDER (SAF2017-87301-R to M.L.M-Ch) MCIU/AEI/FEDER, UE (RTI2018-095134-B-100 to P.A. and RTI2018-099413-B-I00 to RN, Asociación Española contra el Cáncer, Canceres raros (M.L.M-Ch), La Caixa Foundation (to M.L.M-Ch), Ayudas Fundación BBVA a equipos de Investigación Científica 2018 (to M.L.M-Ch), Xunta de Galicia (RN: 2015-CP080 and 2016- PG057), Fundación BBVA (RN), and European Foundation for the Study of Diabetes (RN). ISCIII-FEDER PI17/00535 (to C.G-M.), ISCIII-FEDER CP14/00181 and PI16/00823 (to A.G- R.), and Francisco Cobos Foundation (to A.G-R.). CiC bioGUNE thanks MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016- 0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover

  • Simón, Jorge
  • Ouro, Alberto
  • Ala-Ibanibo, Lolia
  • Presa, Natalia
  • Cardoso Delgado, Teresa de Jesús
  • Martínez-Chantar, María Luz
Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the main causes of chronic liver disease worldwide. NAFLD comprises a group of conditions characterized by the accumulation of hepatic lipids that can eventually lead to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), the fifth most common cancer type with a poor survival rate. In this context, several works have pointed out perturbations in lipid metabolism and, particularly, changes in bioactive sphingolipids, as a hallmark of NAFLD and derived HCC. In the present work, we have reviewed existing literature about sphingolipids and the development of NAFLD and NAFLD-derived HCC. During metabolic syndrome, considered a risk factor for steatosis development, an increase in ceramide and sphigosine-1-phosphate (S1P) have been reported. Likewise, other reports have highlighted that increased sphingomyelin and ceramide content is observed during steatosis and NASH. Ceramide also plays a role in liver fibrosis and cirrhosis, acting synergistically with S1P. Finally, during HCC, metabolic fluxes are redirected to reduce cellular ceramide levels whilst increasing S1P to support tumor growth., This work was supported by grants from Ministerio de Economía, Industria y Competitividad: SAF2017-87301-R (M.L.M.-C.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD (M.L.M.-C.), ELKARTEK 2016, Departamento de Industria del Gobierno Vasco (to M.L.M.-C.), Asociación Española contra el Cáncer (to T.C.D. and M.L.M.-C.), Daniel Alagille award from EASL (to T.C.D.), Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M.-C.), La Caixa Foundation Program (to M.L.M.-C.). We thank Gobierno Vasco-Departamento de Educación for the pre-doctoral grants from 2014 (to N.P.) and 2015 (to J.S.) and the post-doctoral grant from 2017 (to A.O.). We thank MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

  • Fernández-Ramos, David
  • Simón, Jorge
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Delgado, Teresa C.
  • Martínez-Chantar, María Luz
Fernández-Ramos et al., Glycine N-methyltransferase (GNMT) is the most abundant methyltransferase in the liver and a master regulator of the transmethylation flux. GNMT downregulation leads to loss of liver function progressing to fibrosis, cirrhosis, and hepatocellular carcinoma. Moreover, GNMT deficiency aggravates cholestasis-induced fibrogenesis. To date, little is known about the mechanisms underlying downregulation of GNMT levels in hepatic fibrosis and cirrhosis. On this basis, microRNAs are epigenetic regulatory elements that play important roles in liver pathology. In this work, we aim to study the regulation of GNMT by microRNAs during liver fibrosis and cirrhosis. Luciferase assay on the 3'UTR-Gnmt was used to confirm in silico analysis showing that GNMT is potentially targeted by the microRNA miR-873-5p. Correlation between GNMT and miR-873-5p in human cholestasis and cirrhosis together with miR-873-5p inhibition in vivo in different mouse models of liver cholestasis and fibrosis [bile duct ligation and Mdr2 (Abcb4)-/- mouse] were then assessed. The analysis of liver tissue from cirrhotic and cholestatic patients, as well as from the animal models, showed that miR-873-5p inversely correlated with the expression of GNMT. Importantly, high circulating miR-873-5p was also detected in cholestastic and cirrhotic patients. Preclinical studies with anti-miR-873-5p treatment in bile duct ligation and Mdr2-/- mice recovered GNMT levels in association with ameliorated inflammation and fibrosis mainly by counteracting hepatocyte apoptosis and cholangiocyte proliferation. In conclusion, miR-873-5p emerges as a novel marker for liver fibrosis, cholestasis, and cirrhosis and therapeutic approaches based on anti-miR-873-5p may be effective treatments for liver fibrosis and cholestatic liver disease., This work was supported by grants from NIH (US Department of Health and Human services)- R01AT001576 (S.C.L., J.M.M., and M.L.M.-C.), Ministerio de Economía, Industria y Competitividad: SAF2017-87301-R (M.L.M.-C.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD (M.L.M.-C.), ELKARTEK 2016, Departamento de Industria del Gobierno Vasco (to M.L.M.-C.), Asociación Española contra el Cáncer (to T.C.D, P.F.-T. and M.L.M.-C.), Mitotherapeutix (to M.L.M.-C.), Daniel Alagille award from EASL (to T.C.D), Fundación Científica de la Asociación Española Contra el Cancer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M, J.M.B., and M.A), La Caixa Foundation Program (to M.L.M, J.M.B.), FIS: PI15/00892 (to M.F.F), FIS: PI15/01132 and FIS PI18/01075 (to J.M.B.), (to J.M.B.), FIS: PI14/00399 and PI17/00022 (to M.J.P.), Miguel Servet Program (CON14/00129 to J.M.B.), Ramon y Cajal Program (RYC-2015-17755 to M.J.P.), GRUPIN14-052 (to M.F.), PI14/00962 Instituto Carlos III (to J.B.), AECC Scientific Foundation (to J.B.), World Wide Cancer Research (to J.B.), Programma di Ricerca Regione-Università 2007-2009 and 2011-2012, Regione Emilia-Romagna (to E.V.), “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004 to J.M.B.), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M.B.), Department of Health of the Basque Country (2013111173 to J.M.B.; 2015111100 to M.J.P.). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. “Hepacare Project” from Fundación La Caixa, Spain (to M.A.A and C.B.), BiO-Eusko Fundazioa project BIO15/CA/011 (to M.A.A and C.B.). We thank this work produced with the support of a 2017 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation (to M.V.R.). We thank MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644)., Peer reviewed